StreetInsider.com News Articles

Form 3 DANAHER CORP /DE/ For: Oct 09 Filed by: COMAS DANIEL L

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198576.html

Form 3 DANAHER CORP /DE/ For: Oct 09 Filed by: HERSHBERG ROBERT

Fri, 16 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261016/27198572.html

Form 4 DANAHER CORP /DE/ For: Oct 09 Filed by: RALES MITCHELL P

Wed, 14 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27187494.html

Form 4 DANAHER CORP /DE/ For: Oct 09 Filed by: RALES STEVEN M

Wed, 14 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27187490.html

Beckman Coulter Diagnostics appoints Catherine Jennings as president

Wed, 14 Oct 2026 08:31:19 -0400

Beckman Coulter Diagnostics, a subsidiary of Danaher Corporation (NYSE: DHR), announced the appointment of Catherine "Cat" Jennings as president, according to a company statement.

Jennings joins from Boston Scientific, where she most recently served as president of Vascular Therapies, overseeing a global business with approximately $2 billion in annual revenue. She brings more than 20 years of healthcare industry experience.

In her new role, Jennings will oversee the company's strategic, operational and organizational priorities. Beckman Coulter Diagnostics is headquartered in Brea, Calif., and employs more than 10,000 people worldwide.

Kevin O'Reilly, Group Executive of Danaher Diagnostics, said in the statement: "Cat's leadership will

Beckman Coulter Diagnostics Names Catherine Jennings as President

Wed, 14 Oct 2026 08:31:00 -0400

Experienced global healthcare leader to accelerate innovation and
expand its impact for laboratories, clinicians and patients.

BREA, Calif., Oct. 14, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical diagnostics, today announced the appointment of Catherine "Cat" Jennings as President. In this role, Jennings will lead the company's strategic, operational and organizational

Beckman Coulter Diagnostics Names Catherine Jennings as President

Wed, 14 Oct 2026 08:31:00 -0400

Experienced global healthcare leader to accelerate innovation and
expand its impact for laboratories, clinicians and patients.

Danaher and Nvidia partner to integrate AI into lab instruments

Wed, 14 Oct 2026 06:05:50 -0400

Danaher Corporation (NYSE: DHR) announced a collaboration with Nvidia to integrate AI and accelerated computing technologies into scientific instruments and laboratory workflows, according to a company press release dated Oct. 14, 2026.

The companies plan to combine Danaher's scientific instrumentation, automation technologies, and laboratory workflow software with Nvidia's accelerated computing tools, including DGX Spark edge computing, RAPIDS data processing, and BioNeMo Open Models. Initial efforts will focus on a select group of priority instruments, with the possibility of expanding to a broader portfolio.

The collaboration also explores the use of Nvidia Cosmos world models and Omniverse Digital Twins to support laboratory workflows

Danaher Collaborates with NVIDIA to Advance Autonomous Science

Wed, 14 Oct 2026 02:00:00 -0400

Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and data

WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher's broader effort to shape the future of AI-enabled science,

Danaher Collaborates with NVIDIA to Advance Autonomous Science

Wed, 14 Oct 2026 02:00:00 -0400

Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and data

Danaher (DHR) PT Raised to $255 at TD Cowen

Tue, 13 Oct 2026 09:30:47 -0400

TD Cowen analyst Dan Brennan raised the price target on Danaher (NYSE: DHR) to $255.00 (from $236.00) while maintaining a rating.

Form 8-K DANAHER CORP /DE/ For: Oct 09

Tue, 13 Oct 2026 08:53:00 -0400

si-local-file:///var/storage/secattach/20261013/27178107.html

Danaher (DHR) PT Raised to $240 at Morgan Stanley

Tue, 13 Oct 2026 08:23:58 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on Danaher (NYSE: DHR) to $240.00 (from $220.00) while maintaining a Overweight rating.

Danaher adds two directors, expands board to 13 members

Mon, 12 Oct 2026 16:25:15 -0400

Danaher Corporation (NYSE: DHR) appointed Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its board of directors on October 9, 2026, according to a company press release. The board was expanded from 11 to 13 directors to accommodate the appointments.

Comas joined Danaher in 1991 and served as Executive Vice President from April 2005 through December 2020, including as Chief Financial Officer from April 2005 through December 2018. He later served as a senior advisor and consultant to the company through September 2026. He also serves as a director of Fortive Corporation and Veralto Corporation.

Hershberg served as President, Chief Executive

Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors

Mon, 12 Oct 2026 16:25:00 -0400

WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to the Danaher Board of Directors on October 9, 2026. Dr. Hershberg has also been appointed to the Company's Science and Technology Committee. Alan G. Spoon will not stand for reelection at Danaher's 2027 Annual Meeting of Shareholders, retiring from the

Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors

Mon, 12 Oct 2026 16:25:00 -0400

Danaher (DHR) PT Raised to $246 at Baird

Thu, 08 Oct 2026 07:23:10 -0400

Baird analyst Catherine Schulte raised the price target on Danaher (NYSE: DHR) to $246.00 (from $238.00) while maintaining a Outperform rating.

Danaher stock rises 2% on AI-powered autonomous lab plans

Wed, 07 Oct 2026 09:12:24 -0400

Investing.com -- Danaher Corporation (NYSE:DHR) shares gained 2% in premarket trading Wednesday after the company announced plans to launch its first AI-powered autonomous lab for antibody research.

The lab, expected to operate at scale in early 2027, will combine artificial intelligence, robotics and technologies from several Danaher operating companies to help researchers develop custom antibodies and other molecular tools. The company said the facility is designed to deliver up to 8x faster discovery of affinity reagents and unlock up to a tenfold increase in annual reagent generation.

Based at Abcam, a Danaher company, the lab uses AI to create

Danaher stock rises 2% on AI-powered autonomous lab plans

Wed, 07 Oct 2026 09:12:24 -0400

Investing.com -- Danaher Corporation (NYSE:DHR) shares gained 2% in premarket trading Wednesday after the company announced plans to launch its first AI-powered autonomous lab for antibody research.

Based at Abcam, a Danaher company, the lab uses AI to create

Danaher plans AI-powered autonomous lab for antibody research

Wed, 07 Oct 2026 07:01:48 -0400

Danaher Corporation (NYSE: DHR) announced plans to launch an AI-powered autonomous lab designed to help researchers develop custom antibodies and other molecular tools. The lab is expected to operate at scale in early 2027.

Based at Abcam, a Danaher subsidiary, the lab will combine artificial intelligence, robotics, and technologies from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices. Device orchestration and robotic automation were developed in collaboration with Automata, a company that received an investment from Danaher in January 2026.

According to the company's press release, the lab is designed to deliver up

Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab

Wed, 07 Oct 2026 07:00:00 -0400

Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies

WASHINGTON, Oct. 7, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and

Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab

Wed, 07 Oct 2026 07:00:00 -0400

Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies

Danaher (DHR) PT Raised to $255 at Barclays

Wed, 07 Oct 2026 03:49:35 -0400

Barclays analyst Luke Sergott raised the price target on Danaher (NYSE: DHR) to $255.00 (from $230.00) while maintaining a Overweight rating.

Danaher (DHR) PT Raised to $250 at RBC Capital

Mon, 05 Oct 2026 08:53:07 -0400

(Updated - October 5, 2026 8:53 AM EDT)

RBC Capital analyst Dan Leonard raised the price target on Danaher (NYSE: DHR) to $250.00 (from $215.00) while maintaining an Outperform rating.

The analyst commented: "We're increasing our price target on Outperform-rated Danaher (DHR) to $250 from $215. This increase reflects multiple expansion in Danaher's peer group rather than company-specific drivers, though we're more constructive on the company-specific set-up into Q3."

Danaher (DHR) PT Raised to $250 at RBC Capital

Mon, 05 Oct 2026 08:53:07 -0400

(Updated - October 5, 2026 8:53 AM EDT)

RBC Capital analyst Dan Leonard raised the price target on Danaher (NYSE: DHR) to $250.00 (from $215.00) while maintaining an Outperform rating.